Cargando…

Prognostic factors associated with clinical pregnancy in in vitro fertilization using pituitary down-regulation with depot and daily low-dose luteal phase gonadotropin releasing hormone agonists: A single center's experience

AIM: To review the experience on depot-dose, and daily low-dose gonadotropin releasing hormone agonist (GnRHa) long protocols and identify prognostic factors. SETTING AND DESIGN: A chart review was conducted on 2106 depot and 1299 daily low-dose cycles at a university hospital. METHODS: Clinical par...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Caiyun, Huang, Rui, Scherer, Roberta W., Liang, Xiao-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381380/ https://www.ncbi.nlm.nih.gov/pubmed/25838746 http://dx.doi.org/10.4103/0974-1208.153124

Ejemplares similares

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome
por: Inamdar, Dattaprasad B, et al.
Publicado: (2012)

Luteal estradiol supplementation in gonadotropin-releasing hormone antagonist cycles for infertile patients in vitro fertilization
por: Kwon, Su-Kyoung, et al.
Publicado: (2013)

Comparison of luteal phase ovulation induction and ultra-short gonadotropin-releasing hormone agonist protocols in older patients undergoing in vitro fertilization
por: Wang, Tianqi, et al.
Publicado: (2019)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients
por: Martazanova, Bella, et al.
Publicado: (2022)

Single Dose Gonadotropin-Releasing Hormone Agonist Luteal Support in Fresh Embryo Transfer: Variation in Timing, Type, and Dosage
por: Abu, Muhammad Azrai, et al.
Publicado: (2022)

Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort
por: Crawford, E David, et al.
Publicado: (2011)

Functional Ovarian Cysts in Artificial Frozen-Thawed Embryo Transfer Cycles With Depot Gonadotropin-Releasing Hormone Agonist
por: Ji, Hui, et al.
Publicado: (2022)

Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin-releasing hormone agonist
por: Ma, Nieying, et al.
Publicado: (2020)

Gonadotropin-releasing hormone agonist for ovulation trigger – OHSS prevention and use of modified luteal phase support for fresh embryo transfer
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF
por: Carosso, Andrea Roberto, et al.
Publicado: (2021)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: a retrospective cohort study
por: Ying, Yingfen, et al.
Publicado: (2019)

Multiple-dose versus single-dose gonadotropin-releasing hormone agonist after first in vitro fertilization failure associated with luteal phase deficiency: A randomized controlled trial
por: Qu, Danni, et al.
Publicado: (2020)

Luteal Coasting and Individualization of Human Chorionic Gonadotropin Dose after Gonadotropin-Releasing Hormone Agonist Triggering for Final Oocyte Maturation—A Retrospective Proof-of-Concept Study
por: Lawrenz, Barbara, et al.
Publicado: (2018)

Is It Possible to Prevent Ovarian Hyperstimulation Syndrome by Gonadotropin-Releasing Hormone Agonist Triggering and Modified Luteal Support in Patients With Polycystic Ovarian Morphology?
por: Gurbuz, Ali Sami, et al.
Publicado: (2016)

Effects of multiple doses of gonadotropin-releasing hormone agonist on the luteal-phase support in assisted reproductive cycles: A clinical trial study
por: Eftekhar, Maryam, et al.
Publicado: (2021)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
por: Jeon, Min Jin, et al.
Publicado: (2021)

Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization
por: Lee, Hwajeong, et al.
Publicado: (2018)

Administration of gonadotropin-releasing hormone agonist on Day 5 increases luteal blood flow and improves pregnancy prediction accuracy on Day 14 in recipient Holstein cows
por: KANAZAWA, Tomomi, et al.
Publicado: (2017)

Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy
por: Massarotti, C., et al.
Publicado: (2023)

Artificial Endometrial Preparation for Frozen-Thawed Embryo Transfer with or without Pretreatment with Depot Gonadotropin Releasing Hormone Agonist in Women with Regular Menses
por: Azimi Nekoo, Elham, et al.
Publicado: (2015)

Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin‐releasing hormone agonist for women undergoing fertility preservation
por: Hong, Yeon Hee, et al.
Publicado: (2022)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS
por: Eftekhar, Maryam, et al.
Publicado: (2016)

Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case
por: Huang, Tsung-Yi, et al.
Publicado: (2013)

Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment
por: Barbosa, Mariana, et al.
Publicado: (2020)

PMON91 Late Presentation of Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist for Prostate Cancer Treatment
por: Raj, Rishi, et al.
Publicado: (2022)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

Live births from in vitro fertilization-embryo transfer following the administration of gonadotropin-releasing hormone agonist without gonadotropins: Two case reports
por: Li, Mai, et al.
Publicado: (2023)

Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study
por: Drakopoulos, Panagiotis, et al.
Publicado: (2019)

Use of gonadotropin-releasing hormone (GnRH) agonist trigger in fertility preservation for patients with inherited genetic disorders
por: Merkison, Jamie, et al.
Publicado: (2022)

MON-239 Pituitary Apoplexy Induced by Gonadotropin-Releasing Hormone Agonist Administration: A Rare Complication of Prostate Cancer Treatment
por: Barbosa, Mariana Marques, et al.
Publicado: (2020)

Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review
por: Raj, Rishi, et al.
Publicado: (2021)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fbeg62tp179q206fl58aubbkgu